Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit

Award Number: U24CA288185
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/22/2023
PERIOD OF PERFORMANCE END DATE: 08/31/2028

Group Awards By:

View Award Description

Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit - PROJECT SUMMARY Liquid biopsy is a clinical test that involves the analysis of various biomarkers present in the blood or other types of body fluids. It enables the detection of cancer at an earlier stage than traditional imaging or tissue biopsy methods, and thus can lead to reduction of cancer mobility and mortality. As one of the most promising solutions for cancer early detection, liquid biopsy has the potential to revolutionize cancer diagnosis, providing patients with more effective and less invasive care. The liquid biopsy analytes include circulating tumor cells (CTCs), circulating tumor DNA, which is part of cell-free DNA (cfDNA), extracellular vesicles, as well other tumor associated RNAs, proteins and metabolites. These analytes typically have very low levels in blood or other types of body fluid of early-stage cancer patients, leading to difficulties in obtaining reproducible results and low sensitivity and specificity for cancer early detection. While many new assays and techniques have been developed to tackle these challenges, validation of these assays/techniques in different populations and/or cancer types poses many challenges, and these are the main areas of research supported by the liquid biopsy consortium (LBC). As Data Management and Coordinating Unit (DMCU) of LBC, we will support state- of-the-art statistical methods for study design and data analysis, the coordination, implementation, and conduct of collaborative studies across the consortium and work closely with LBC investigators on data analysis by statistical methods, machine Learning modeling and Artificial Intelligence. We will also support consortium coordination and data management, including identification and adoption of standard data elements for liquid biopsy studies. We seek to establish the DMCU as a leading center for innovation and resources in liquid biopsy research, and to enhance, improve and maintain LBC network integration and coordination.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $792,000 )
2026	2026	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	001	4	8/26/2026	NON-COMPETING CONTINUATION	$792,000
2026	2025	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	3	4/21/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $792,000

Issue Date FY: 2025 ( Subtotal = $792,000 )
2025	2025	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	001	3	9/3/2025	NON-COMPETING CONTINUATION	$792,000
2025	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	2	3/21/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $792,000

Issue Date FY: 2024 ( Subtotal = $752,400 )
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	001	2	8/22/2024	NON-COMPETING CONTINUATION	$752,400
2024	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	1	10/27/2023	NEW	$0
														Subtotal = $752,400

Issue Date FY: 2023 ( Subtotal = $792,000 )
2023	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	1	9/22/2023	NEW	$792,000
														Subtotal = $792,000

Grand Total All Awards = $3,128,400

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit

Award Number: U24CA288185

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/22/2023

PERIOD OF PERFORMANCE END DATE: 08/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer